Deterministic LLC platform for targeted epigenetic signaling and delivery
An innovative platform utilizing Lyotropic Liquid Crystalline nanostructures and the SEI Reasoning Kernel for targeted delivery and modulation of epigenetic marks in plants. This system ensures stability and efficacy under field conditions, providing a pathway for non-transgenic crop improvement.
Overview
This solution introduces a novel platform designed to deliver and modulate epigenetic marks in plants using Lyotropic Liquid Crystalline (LLC) nanostructures and the SEI Reasoning Kernel. The platform aims to address the challenge of delivering epigenetic effectors in a stable and controlled manner, ensuring effective uptake and temporal modulation. This approach leverages thermodynamically stable LLC matrices to protect and deliver payloads, with the SEI Kernel providing a deterministic framework for modeling uptake and diffusion, enhancing the precision and reliability of epigenetic interventions.
Technical specifications
Key features:
- Utilizes cubic and hexagonal phase LLC matrices to encapsulate and protect epigenetic effectors.
- SEI Reasoning Kernel models uptake and diffusion kinetics, ensuring targeted and reversible epigenetic modulation.
- Designed for sprayable, foliar application, facilitating easy integration into agricultural practices.
- Supports non-transgenic crop improvement by enabling tunable phenotypic shifts without altering DNA sequences.
Technology readiness level
The platform is currently at Technology Readiness Level 3, with initial validation phases focusing on computational modeling, formulation synthesis, and proof of concept in greenhouse settings. Future developments aim to demonstrate scalable applications in real-world agricultural environments.
About MyMonitor Corporation
MyMonitor Corporation is a healthcare technology company that has developed an AI-driven platform designed to modernize dermatological assessment and clinical research. The system functions by converting standard skin images into structured, objective clinical data, aiming to reduce diagnostic variability and improve the precision of skin condition management. A core feature of the platform is its use of melanin-aware imaging technology, which is intended to support more equitable and inclusive diagnostics across diverse skin tones. Beyond image analysis, the platform provides tools that integrate with healthcare systems and electronic health records to streamline workflows for clinicians and stakeholders in the dermatological field.
This technology is intended to assist a wide range of organizations, including hospitals, clinics, and health systems, by enhancing diagnostic accuracy and facilitating more efficient patient care. Additionally, the platform addresses needs within clinical trials by offering smart recruitment strategies and ensuring diverse patient enrollment. By shifting dermatology toward a more data-driven approach, MyMonitor seeks to transform subjective visual assessments into measurable medical insights, ultimately aiming to improve patient outcomes and support research evidence generation from bedside to benchside. The company, which is based in the United States, focuses on closing the gap between traditional dermatological practice and modern data science.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.